A phase II trial of ipilimumab, nivolumab, or ipilimumab and nivolumab with or without azacitidine in relapsed or refractory myelodysplastic neoplasms

Ian M. Bouligny,Guillermo Montalban-Bravo,Koji Sasaki,Naval Daver,Elias Jabbour,Yesid Alvarado,Courtney D. DiNardo,Farhad Ravandi,Gautam Borthakur,Naveen Pemmaraju,Tapan Kadia,Lucia Masarova,Koichi Takahashi,Michael Andreeff,Alexandre Bazinet,Hui Yang,Rashmi Kanagal,Sherry Pierce,Meghan Meyer,Xuelin Huang,Guillermo Garcia-Manero

DOI: https://doi.org/10.1038/s41375-024-02457-7

2024-11-22

Leukemia

Abstract:Patients with myelodysplastic neoplasms (MDS) who progress on hypomethylating agents have poor outcomes [1,2,3]. There are no standard treatment approaches in this setting; while high-dose chemotherapy followed by allogeneic stem cell transplant remains a curative option for higher-risk MDS, advanced age and significant comorbidities preclude this approach for many patients [4]. In these cases, novel therapies are urgently needed. Programmed cell death-ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA4) are upregulated in hypomethylating agent failure MDS [5]. PD-L1 on the surface of MDS cells binds to PD-1 on T cells, facilitating immune evasion [6]. Similarly, CTLA4 on T cells binds to B7 on MDS cells, stifling T-cell receptor activation and contributing to immune escape [7]. These findings provide a rationale for assessing PD-1 and CTLA4 blockade in MDS following hypomethylating agent exposure [7]. Ipilimumab and nivolumab are fully human IgG1k monoclonal antibodies that target CTLA4 and PD-1, respectively [8, 9]. Both monotherapy and combination immunotherapy approaches are safe and effective in solid tumors and lymphomas; however, their safety and efficacy in relapsed or refractory MDS remains unclear.

oncology,hematology